NASDAQ:RXDX - Ignyta Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$26.95 0.00 (0.00 %)
(As of 11/20/2018 04:00 PM ET)
Previous Close$26.95
Today's Range$26.95 - $26.95
52-Week Range$5.80 - $27.10
Volume254,655 shs
Average Volume3.04 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Ignyta, Inc. is a biotechnology company. The Company is focused on precision medicine in oncology. The Company is pursuing an integrated therapeutic (Rx) and companion diagnostic (Dx) strategy for treating cancer patients. The Company's pipeline includes various compounds, such as entrectinib, RXDX-105, taladegib and RXDX-106. Entrectinib is an orally bioavailable, central nervous system (CNS)-active, small molecule tyrosine kinase inhibitor directed to the tropomyosin receptor kinase (TRK) family of tyrosine kinase receptors (TRKA, TRKB and TRKC), ROS1 and anaplastic lymphoma kinase (ALK) proteins. RXDX-105 is an orally bioavailable, vascular endothelial growth factor receptor (VEGFR)-sparing, small molecule tyrosine kinase inhibitor of rearranged during transfection (RET). Taladegib is an orally bioavailable, small molecule hedgehog/smoothened antagonist. RXDX-106 is a pseudo-irreversible, small molecule inhibitor of TYRO3, AXL and MER (collectively TAM), and c-MET.

Receive RXDX News and Ratings via Email

Sign-up to receive the latest news and ratings for RXDX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry N/A
Current SymbolNASDAQ:RXDX
Previous Symbol


Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A


EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A


Outstanding SharesN/A
Market Cap$0.00
OptionableNot Optionable

Ignyta (NASDAQ:RXDX) Frequently Asked Questions

What is Ignyta's stock symbol?

Ignyta trades on the NASDAQ under the ticker symbol "RXDX."

How were Ignyta's earnings last quarter?

Ignyta Inc (NASDAQ:RXDX) announced its earnings results on Tuesday, November, 7th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.03. View Ignyta's Earnings History.

What price target have analysts set for RXDX?

4 analysts have issued 12-month price objectives for Ignyta's shares. Their predictions range from $27.00 to $27.00. On average, they expect Ignyta's share price to reach $27.00 in the next year. This suggests a possible upside of 0.2% from the stock's current price. View Analyst Price Targets for Ignyta.

What is the consensus analysts' recommendation for Ignyta?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ignyta in the last year. There are currently 4 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Ignyta.

What are Wall Street analysts saying about Ignyta stock?

Here are some recent quotes from research analysts about Ignyta stock:
  • 1. Cantor Fitzgerald analysts commented, "The merger was announced on December 22, 2017, and the transaction was completed on February 8, 2018." (2/9/2018)
  • 2. According to Zacks Investment Research, "Ignyta, Inc. is a biotechnology company. It develops precision medicine with integrated Rx/Dx solutions for cancer patients. The company focuses on the development of RXDX-101, its proprietary oral tyrosine kinase inhibitor that targets solid tumor indications, and advancing its novel Spark discovery programs that leverage its proprietary cancer genomic and epigenomic knowledge bases. Ignyta, Inc. is based in San Diego, California. " (1/17/2018)

Has Ignyta been receiving favorable news coverage?

News stories about RXDX stock have trended somewhat negative this week, InfoTrie Sentiment reports. The research firm rates the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Ignyta earned a media sentiment score of -1.2 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 5.0 out of 10, meaning that recent news coverage is somewhat likely to have an effect on the company's share price in the next few days.

Who are Ignyta's key executives?

Ignyta's management team includes the folowing people:
  • Jonathan E. Lim M.D., Chairman of the Board, President, Chief Executive Officer, Co-Founder (Age 45)
  • Jacob M. Chacko M.D., Chief Financial Officer (Age 38)
  • Zachary Hornby, Chief Operating Officer (Age 38)
  • Valerie Harding Start Ph.D., Senior Vice President - Chemistry, Manufacturing, and Controls (Age 57)
  • Christian V. Kuhlen M.D. Esq., General Counsel, Secretary (Age 44)
  • William R. McCarthy, Chief Business Officer (Age 45)
  • Pratik S. Multani M.D., Chief Medical Officer (Age 50)
  • James A. Bristol Ph.D., Independent Director (Age 70)
  • Alexander W. Casdin, Independent Director (Age 49)
  • Heinrich Dreismann Ph.D., Independent Director (Age 64)

How do I buy shares of Ignyta?

Shares of RXDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ignyta's stock price today?

One share of RXDX stock can currently be purchased for approximately $26.95.

What is Ignyta's official website?

The official website for Ignyta is

How can I contact Ignyta?

Ignyta's mailing address is 4545 Towne Centre Ct, SAN DIEGO, CA 92121-1900, United States. The biopharmaceutical company can be reached via phone at +1-858-2555959.

MarketBeat Community Rating for Ignyta (NASDAQ RXDX)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  250 (Vote Outperform)
Underperform Votes:  139 (Vote Underperform)
Total Votes:  389
MarketBeat's community ratings are surveys of what our community members think about Ignyta and other stocks. Vote "Outperform" if you believe RXDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RXDX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/20/2018 by Staff

Featured Article: Yield Curve

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel